Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.

[1]  Dina V. Hingorani,et al.  Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability , 2019, Molecular Cancer Therapeutics.

[2]  D. Hallahan,et al.  PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[3]  M. Liedtke,et al.  Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study , 2019, Cancer.

[4]  R. Weichselbaum,et al.  Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities , 2019, Cancer journal.

[5]  H. Arami,et al.  Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy , 2018, Oncotarget.

[6]  C. N. Coleman,et al.  Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15–18 October 2017; Cancun, Mexico , 2018, Radiation Research.

[7]  S. Adams,et al.  Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes , 2018, Molecular Cancer Therapeutics.

[8]  J. Sarkaria,et al.  Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. , 2018, The Lancet. Oncology.

[9]  A. Berkenblit,et al.  Antibody-Drug Conjugates for Cancer Treatment. , 2018, Annual review of medicine.

[10]  Karra A. Jones,et al.  Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize , 2016, Nature Communications.

[11]  Richard A. Adams,et al.  Clinical development of new drug–radiotherapy combinations , 2016, Nature Reviews Clinical Oncology.

[12]  A. Hagemeijer,et al.  Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Pelizzari,et al.  Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment. , 2016, Molecular pharmaceutics.

[14]  D. Hallahan,et al.  Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers , 2016, Oncotarget.

[15]  S. Anand,et al.  Kinase-independent role for CRAF-driving tumour radioresistance via CHK2 , 2015, Nature Communications.

[16]  Manish R. Patel,et al.  Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. , 2015, The Lancet. Oncology.

[17]  Andrew M. Gross,et al.  Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. , 2015, Oral oncology.

[18]  R. Tsien,et al.  Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. , 2015, Cancer research.

[19]  R. Tsien,et al.  Dual Targeting of Integrin αvβ3 and Matrix Metalloproteinase-2 for Optical Imaging of Tumors and Chemotherapeutic Delivery , 2014, Molecular Cancer Therapeutics.

[20]  John Buatti,et al.  Lessons Learned from Radiation Oncology Clinical Trials , 2013, Clinical Cancer Research.

[21]  David G. Kirsch,et al.  Strategies for optimizing the response of cancer and normal tissues to radiation , 2013, Nature Reviews Drug Discovery.

[22]  C. N. Coleman,et al.  Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. , 2013, Journal of the National Cancer Institute.

[23]  R. Weichselbaum,et al.  New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology , 2013, Science Translational Medicine.

[24]  Paul Steinbach,et al.  Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. , 2013, Cancer research.

[25]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[26]  C. Teng,et al.  MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis , 2012, Oncogene.

[27]  Joshua D. Lawson,et al.  DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. , 2011, Future oncology.

[28]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[29]  Jonathan Maybaum,et al.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. , 2010, Cancer research.

[30]  James B. Mitchell,et al.  In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762 , 2010, Clinical Cancer Research.

[31]  M. Moses,et al.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  James B. Mitchell,et al.  In Vitro and In Vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor , 2009 .

[33]  Aideen Long,et al.  Statistical methods for analysis of high-throughput RNA interference screens , 2009, Nature Methods.

[34]  Roger Y Tsien,et al.  Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[35]  Roger Y Tsien,et al.  In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[36]  J. S. Rao,et al.  Inhibition of matrix metalloproteinase‐2 enhances radiosensitivity by abrogating radiation‐induced FoxM1‐mediated G2/M arrest in A549 lung cancer cells , 2009, International journal of cancer.

[37]  P. Senter,et al.  Novel peptide linkers for highly potent antibody-auristatin conjugate. , 2008, Bioconjugate chemistry.

[38]  Roger Y Tsien,et al.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Weiling Zhao,et al.  Radiation-Induced Up-regulation of Mmp2 Involves Increased mRNA Stability, Redox Modulation, and MAPK Activation , 2004, Radiation research.

[40]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[41]  Jeffrey W. Smith,et al.  MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αvβ3 Promotes Maturation of MMP-2 in Breast Carcinoma Cells , 2001 .

[42]  M. Secic,et al.  Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck , 2000, Cancer.

[43]  J. Scholefield,et al.  Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer , 2000, British Journal of Cancer.

[44]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[46]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. James.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin , 1996, The Lancet.

[48]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[49]  W. Hong,et al.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. , 1991, The New England journal of medicine.

[50]  A. Strongin,et al.  MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. , 2001, Experimental cell research.